Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children
- David Hutton; Lisa Prosser; Angela Rose; Kerra Mercon; Ismael Ortega-Sanchez; Andrew Leidner
Access Resources
About
This study evaluated the cost-effectiveness of using nirsevimab to prevent respiratory syncytial virus (RSV) in infants and high-risk children. By analyzing healthcare data, it was estimated that nirsevimab could prevent many outpatient visits, emergency department visits, and hospitalizations. The cost per quality-adjusted life year (QALY) saved was found to be $153,517 for infants in their first RSV season and $308,468 for high-risk children in their second season. Overall, nirsevimab was considered cost-effective, especially for high-risk individuals with increased RSV-related risks and costs.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.